Aquestive Therapeutics (Formerly known as MonoSolRx)

227 articles with Aquestive Therapeutics (Formerly known as MonoSolRx)

• Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

  3/7/2023

  Aquestive Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a progress update on the key 2023 objectives previously outlined by the Company.

• Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

  3/1/2023

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to March 15th.

• Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

  2/22/2023

  Aquestive Therapeutics, Inc. today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023.

• Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

  2/21/2023

  Aquestive Therapeutics, Inc. today announced that four late breaking posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of AQST-109 epinephrine sublingual film will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting, which will be held from February 24-27 in San Antonio, Texas.

• Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

  1/6/2023

  Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives.

• Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

  12/22/2022

  Aquestive Therapeutics, Inc. today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.

• Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

  11/29/2022

  Aquestive Therapeutics, Inc. announced the publication of a crossover food effect pharmacokinetic study of diazepam nasal spray in the peer-reviewed scientific journal Epilepsia.

• Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - November 15, 2022

  11/15/2022

  Aquestive Therapeutics, Inc. announced that the management team will participate in the two upcoming investor conferences as follows.

• Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

  11/9/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting.

• Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/1/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.

• Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.

  10/27/2022

  Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced a transaction to acquire an exclusive license for Sympazan® (clobazam) oral film from Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods.

• Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

  10/27/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today a transaction to license Sympazan® (clobazam) oral film to Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients.

• Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

  10/19/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third quarter ended September 30, 2022, and provide an update on recent developments in its business after market close on Tuesday, November 1, 2022.

• 

  FDA Review: Phanes, Pfizer, GSK and More

  10/14/2022

  The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions.  

• Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

  10/11/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced positive written feedback from the U.S. Food and Drug Administration (FDA) for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls (CMC) for its AQST-109 epinephrine sublingual film for the treatment of severe allergic reaction including anaphylaxis.

• Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

  9/28/2022

  Aquestive Therapeutics, Inc. today announced it has entered a license, and supply agreement for Libervant™ (diazepam) Buccal Film with Pharmanovia, a global lifecycle management healthcare company, for treatment of prolonged or acute, convulsive seizures.

• Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

  9/27/2022

  Aquestive Therapeutics, Inc. announced positive topline results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.

• Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

  9/12/2022

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts.

• 

  FDA Review: Immusoft, BioCryst, Intellia and More

  9/5/2022

  The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.

• Aquestive Therapeutics to Participate in Two Investor Conferences in September

  8/31/2022

  Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September.